ICMR signs MoAs to advance first-in-human clinical trials for four promising molecules

Photograph used for representational purposes only
| Photo Credit: Getty Images/iStockphoto

The Indian Council of Medical Research (ICMR) has formalised Memorandums of Agreement (MoAs) with multiple sponsors under its ‘Network for Phase 1 Clinical Trials’. The agreements mark an entry into first-in-human clinical trials for four promising molecules, the council said on Saturday.

These include collaborative research over a small molecule for multiple myeloma with Aurigene Oncology Limited; partnering for Zika vaccine development with Indian Immunologicals Limited; coordinating a seasonal influenza virus vaccine trial with Mynvax Private Limited; and CAR-T cell therapy advancement study for a new indication of chronic lymphocytic leukaemia with ImmunoACT. 

“This initiative is a crucial step towards establishing India as a leader in the clinical development of pharmaceutical agents,” the council said.

Union Health Minister J.P. Nadda said that the collaboration between ICMR and prominent industry and academic partners is a key milestone in the pursuit of affordable and accessible cutting edge treatments for all citizens. He noted that the initiative positioned India to emerge as a global leader in healthcare innovation.

Rajiv Bahl, Director General, ICMR, said that establishing the first phase of clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting edge treatments.

The ICMR’s ‘Network for Phase 1 Clinical Trials’ comprises four strategically located institutions across India — the King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai; the Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai; the SRM Medical College Hospital and Research Centre, Kattankulathur; and the Postgraduate Institute of Medical Education and Research, Chandigarh. They are supported by the Central Coordinating Unit at the ICMR’s headquarters in New Delhi.

The network is designed to enhance India’s capacity to conduct early phase clinical trials, supported by robust infrastructure and dedicated manpower at each trial site, ensuring smooth and effective operations.